Cantor Fitzgerald, L. P. Viking Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $2.48 Billion
- Q4 2024
A detailed history of Cantor Fitzgerald, L. P. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 9,450 shares of VKTX stock, worth $321,961. This represents 0.02% of its overall portfolio holdings.
Number of Shares
9,450Holding current value
$321,961% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
466Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$205 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$168 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$88.4 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$73.5 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.61B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...